Pharmacovigilance – News and Features

The US Food and Drug Administration (FDA) has approved Zepbound™ (tirzepatide) for use in conjunction with a reduced-calorie diet and increased exercise to help obese adults manage their bodyweight.

Researchers have developed an effective and flexible antimicrobial material that could be used to coat medical devices placed inside the body, helping to prevent infection without drugs.

A promising new cancer therapy also appears extremely potent against one of the world’s most devastating infectious diseases: tuberculosis (TB). Scientists found the therapy dramatically reduces TB growth, even for bacteria that are drug-resistant.

Researchers have discovered previously unknown changes in a specific type of liver cells, potentially opening avenues for a new treatment for liver fibrosis, a potentially life-threatening condition.

Researchers developed an improved method to study Parkinson’s disease in the lab. Along the way, researchers also uncovered clues that may help scientists figure out how to detect Parkinson’s earlier and point the way toward better treatments.

Physical activities in the morning, associated with daily patterns of sleep/wake cycle, convey timing information from the light-sensitive central clock in the brain to the weight-bearing skeletal tissues.

A study of newly created databases of medulloblastoma has found that patients with tumors containing circular extrachromosomal DNA are twice as likely to relapse and three times as likely to die within five years of diagnosis.

Disrupting one gene in CAR T cells used for cancer therapy makes them more potent and able to fight the cancer for longer, reports a new study.

A small molecule drug, one of 27 million screened in a library of potential new drugs, has shown promise as a painkiller, outperforming gabapentin for treating four types of chronic pain.

Andrew Schulman explores why we need allogeneic therapies, the importance of collaboration to keep the momentum, and challenges and predictions for the future.